Industry News Roundup
This article was originally published in The Tan Sheet
Executive Summary
Sipes directs CDER Regulatory Policy; non-HFC propellant in Dr. Smith’s sprays; Bayer prioritizes health care investment; EMA oversight switch criticized; marketing, development changes At GNC; Pharmavite hires Kellogg, NBTY execs; and ‘Turtle Power’ for Colgate Kids Mouthwash.
You may also be interested in...
People In Brief: Maves at USP, Toll at Pharmavite, Lacik heads Reckitt North America
Maves is USP’s development SVP; Pharmavite takes on Toll as sales exec; Lacik shifts to head Reckitt North America; Rainbow Light adds marketing and sales VPs; Lelinski heads Walgreens health and wellness; more People In Brief.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.